{"ticker": {"uuid": "9c894385-342a-44a1-8017-35baf44d45d2", "symbol": "XGN", "name": "Exagen Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "ETFs Investing in Exagen, Inc. Stocks", "summary": "This article identifies ETFs that hold stocks of Exagen, Inc. (E08A), a medical/nursing services company. It lists two specific ETFs, iShares Microcap ETF (IWC) and Invesco NASDAQ Future Gen 200 ETF (QQQS), detailing their market value, weight of Exagen stock, issuer, management ", "url": "https://www.tradingview.com/symbols/TRADEGATE-E08A/etfs/", "source_name": "TradingView", "published_at": "2026-07-13T00:12:33", "published_display": "13 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc focuses on autoimmune diagnostics as investors watch strategy", "summary": "Exagen Inc, a specialized diagnostics company, is capturing investor attention with its focus on autoimmune disease diagnostics, particularly systemic lupus erythematosus and rheumatoid arthritis. The company's strategy involves building a strong testing portfolio, securing comme", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exagen-inc-focuses-on-autoimmune-diagnostics-as-investors-watch-strategy/69716857", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T18:41:56", "published_display": "07 Jul 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen(XGN) Stock Options Chain | Quotes & News", "summary": "This document appears to be a placeholder or an incomplete article about Exagen (XGN) stock options, quotes, and news. No actual content beyond the title is provided, making it impossible to extract further details.", "url": "https://www.moomoo.com/stock/XGN-US/options-chain?chain_id=Name1K9-3FXPhg.1l04rc0&global_content=%7B%22promote_id%22%3A13643,%22sub_promote_id%22%3A47,%22f%22%3A%22www.moomoo.com%2Fsg%2Flearn%2Fdetail-what-is-an-investment-portfolio-38083-2110200026%22%7D", "source_name": "Moomoo", "published_at": "2026-07-06T11:11:19", "published_display": "06 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XGN - Exagen Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Exagen Inc. (XGN), covering its recent stock performance, key financial metrics like market capitalization, income, sales, and various ratios. It also includes information on insider and institutional ownership, analyst recom", "url": "https://finviz.com/stock?t=XGN&ty=ocv&ta=1&p=d&ov=list_strike&s=10", "source_name": "Finviz", "published_at": "2026-07-02T21:09:33", "published_display": "02 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "This page provides financial information for Exagen Inc. (NASDAQ: XGN) on TradingView, specifically focusing on its Price to Sales (forward) metric. The content confirms that the market was closed at the time of viewing, with no trades occurring.", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T22:41:56", "published_display": "30 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for Exagen Inc. (NASDAQ: XGN). It is presented within the context of TradingView's financial analysis tools, indicating that the data is provided by ICE Data Services and FactSet. The content is primarily a d", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T08:41:21", "published_display": "30 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support Level - Momentum Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPc1F4VTdabnVNeVdaS190SnBtTzJ5dm94RG9qVXc2TEFmVlE1R3d3YjdreXZ0dVlBamlnYTh2bDU2TnlUTl9INkZKOWJlTFFXLWh4dVBNaWNka00yRExieVdnYV85VjdoVl9BcmlhanNHaW05d0QxNEI4dE1FVFJ5WVBsYlZkRW0zQWtsUHkyakNXOHhLeUtDUWtEbHVJcFJYRlVNMUpNbVl4S28teWNjNTVoZ0JmTUVPMkM4?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support Level - NAAIM Leverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNdEo0NlRfQTlfUTlSVnVoM000VEFnd292akRmZm0xdXJhYm92Q255MlhYZklVRE9xbFdUQlBmT0g1MGx5WXhCcEY3RnJ6TkVHZGpOMm9wSWVZWkFLTkpJckFnazNLc3ItTzEtZDZOa2hHRjk4UVpsWlo2empWQjRvVHBWTmJUWjdGbTYwclBQZ0U0Wmo5MUk3TFJoVjNYdkgxRy05b3ZMd19XZVRLWTNqa0NlbVg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Exagen, Inc. \u2013 LS:A2PRXT", "summary": "This article provides financial information for Exagen, Inc. (A2PRXT) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of viewing. The content appears to be a stub or an incomplete dat", "url": "https://www.tradingview.com/symbols/LS-A2PRXT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:40:25", "published_display": "30 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "This article provides financial context for Exagen Inc. (NASDAQ: XGN), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial snapshot or data point from TradingView, without additional analysis or narrative.", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T17:39:14", "published_display": "29 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2PRXT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Exagen, Inc. (A2PRXT) stock, including analyst price targets, past performance, and key financial data. According to analysts, the stock has a max estimate of 8.79 EUR and a min estimate of 7.03 EUR. The article also covers reported earnings, ", "url": "https://www.tradingview.com/symbols/LS-A2PRXT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T16:39:15", "published_display": "29 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "The article focuses on the \"Price to book forward\" metric for Exagen Inc. (NASDAQ: XGN). It provides general financial and market information related to the company within the TradingView platform, without specific financial figures or detailed analysis. The content appears to be", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:10:52", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Exagen, Inc. \u2013 GETTEX:E08A", "summary": "This article provides financial information for Exagen, Inc. (GETTEX:E08A), specifically focusing on its Enterprise Value to EBIT forward metric. The content highlights the company's financial data as part of its stock market listing on Gettex, indicating a focus on investor-rela", "url": "https://www.tradingview.com/symbols/GETTEX-E08A/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:09:22", "published_display": "28 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "This article displays the forward Enterprise Value to EBITDA for Exagen Inc. (NASDAQ: XGN) on TradingView. It provides financial data related to the company, indicating the market is currently closed with no trades. The information is presented on the TradingView platform, which ", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:41:10", "published_display": "28 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "The article provides financial information for Exagen Inc. (NASDAQ:XGN), specifically highlighting its enterprise value to revenue forward metric. This data is presented within the context of TradingView's platform, offering an overview of the company's financials for market anal", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:35", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen, Inc. Actuals & Estimates (NASDAQ:XGN)", "summary": "This article provides key financial actuals, estimates, and analyst forecasts for Exagen Inc. (NASDAQ: XGN). It details recent stock performance, future price predictions, upcoming earnings dates, and current financial metrics like market capitalization, revenue, and EBITDA. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:40:48", "published_display": "25 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XGN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Exagen Inc. (XGN) stock, including its current price, analyst forecasts, and various financial metrics. It highlights the company's price target of $8.57, with analysts predicting a maximum of $10.00 and a minimum of $8.00. The article also co", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:48", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Initiates Exagen at Buy With $8 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/roth-capital-initiates-exagen-buy-112451913.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:24:51+00:00", "published_display": "25 Jun 2026 11:24", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat", "summary": "Roth Capital has initiated coverage on Exagen (XGN) with a Buy rating and a price target of $8.00. While analysts see potential upside, GuruFocus indicates the stock is currently 51.0% overvalued with a GF Value\u2122 of $3.00, suggesting caution due to mixed financial metrics and mod", "url": "https://www.gurufocus.com/news/8931447/xgn-initiates-coverage-on-exagen-roth-capital-assigns-buy-rating", "source_name": "GuruFocus", "published_at": "2026-06-25T12:11:42", "published_display": "25 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Exagen Inc For: 24 June By Investing.com", "summary": "This article reports on the filing of Form 4 for Exagen Inc. (XGN) on June 24th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article also provides curre", "url": "https://za.investing.com/news/stock-market-news/form-4-exagen-inc-for-24-june-93CH-4342387", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T05:40:48", "published_display": "25 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst", "summary": "Roth Capital has initiated coverage of Exagen (XGN) with a Buy rating and an $8 price target, driven by the strength of its autoimmune testing range, particularly the AVISE CTD test. Despite a moderate GF Score\u2122 of 58 and concerns about financial strength and profitability, the c", "url": "https://www.gurufocus.com/news/8930745/exagen-xgn-gains-buy-rating-with-8-price-target-from-analyst", "source_name": "GuruFocus", "published_at": "2026-06-25T04:10:57", "published_display": "25 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Exagen Inc For: 22 June By Investing.com", "summary": "This article announces the filing of Form 4 for Exagen Inc. on June 22. It is a brief financial news update from Investing.com reporting the regulatory filing related to insider transactions for the company.", "url": "https://au.investing.com/news/stock-market-news/form-4-exagen-inc-for-22-june-93CH-4498466", "source_name": "Investing.com Australia", "published_at": "2026-06-23T03:11:37", "published_display": "23 Jun 2026 03:11", "sentiment": "negative", "sentiment_pct": 42, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) director granted 37,500 stock options at $4.31 strike", "summary": "Exagen Inc. director Chas McKhann was granted 37,500 stock options at an exercise price of $4.31 per share. These options will vest fully on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues his board service. Fol", "url": "https://www.stocktitan.net/sec-filings/XGN/form-4-exagen-inc-insider-trading-activity-a829ca61bb89.html", "source_name": "Stock Titan", "published_at": "2026-06-22T17:11:38", "published_display": "22 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31", "summary": "Exagen Inc. director Frank Stokes was granted 37,500 stock options at an exercise price of $4.31 per share. These options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues his board service. Following", "url": "https://www.stocktitan.net/sec-filings/XGN/form-4-exagen-inc-insider-trading-activity-75ddec22e69b.html", "source_name": "Stock Titan", "published_at": "2026-06-22T17:11:37", "published_display": "22 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) director Scott Kahn receives 37,500 stock options grant", "summary": "Exagen (XGN) director Scott D. Kahn was granted 37,500 stock options with an exercise price of $4.31 per share, expiring on June 8, 2036. These options will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, provided Kahn re", "url": "https://www.stocktitan.net/sec-filings/XGN/form-4-exagen-inc-insider-trading-activity-d0ddb7fa69bb.html", "source_name": "Stock Titan", "published_at": "2026-06-22T17:11:37", "published_display": "22 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOM1dyWkVoVWkxT0x0bXpOa21GQjBCMlozcmE2Z0gwRU9LcVlwUGtYRTJMZVY2NTQtZE5RUklja2JIYzVGLVZzNTdLOFQ4TVJlRE1zajZ6alM4MGNJRElzMnctYzFGMUJwblJOZ28wMkF0dElCUXRkVG15blZXbEFlQjFTLXB4Y3FaVHJJdWI5UTdjX0Y1WThNdA?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Exagen Inc (XGN), noting its current valuation score of 7.76, placing it 56th out of 76 in the Healthcare Providers & Services industry. The P/E ratio is reported as -5.10, with other key metrics like P/B, P/S, and P/CF not yet discl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:54", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Exagen Inc (XGN)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock performance data for XG", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:15", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Exagen Inc (XGN), detailing its performance across various business segments. It shows that Commercial, Government, and Client segments are the primary contributors to the company's revenue, with specific proportions for each. The dat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:15", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Exagen Inc (XGN) currently holds a financial score of 6.90, ranking 59 out of 76 in the Healthcare Providers & Services industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue saw an 11.67% year-over-year increase, with ne", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T14:40:41", "published_display": "17 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Exagen Inc (XGN), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. The stock currently has a price momentum score of 8.90, trading between resistance at", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/technical", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:34", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Institutional Confidence", "summary": "Exagen Inc (XGN) has an institutional shareholding score of 5.00, placing it 49th out of 76 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 58.04%, marking a 7.71% quarter-over-quarter decrease. James Simons is the largest inst", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:34", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Exagen Inc (XGN) has an earnings forecast score of 8.57, ranking 10th in the Healthcare Providers & Services industry, with an average analyst price target of $15.00. Based on 7 analysts, the stock currently holds a \"Buy\" rating. The company's expected revenue for the next quarte", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:34", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Shareholders Approve Directors, Auditor and Pay Package", "summary": "Exagen Inc. held its 2026 annual meeting where shareholders re-elected two Class I directors, Tina S. Nova and Scott Kahn, to three-year terms. They also ratified BDO USA, P.C. as the independent auditor and approved the compensation for named executive officers, indicating stron", "url": "https://www.theglobeandmail.com/investing/markets/stocks/XGN-Q/pressreleases/2408837/exagen-shareholders-approve-directors-auditor-and-pay-package/", "source_name": "The Globe and Mail", "published_at": "2026-06-11T12:08:55", "published_display": "11 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exagen-announces-publication-systematic-review-130000586.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T13:00:00+00:00", "published_display": "01 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/much-upside-left-exagen-xgn-135501041.html", "source_name": "Zacks", "published_at": "2026-05-28T13:55:01+00:00", "published_display": "28 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOM3RoR2stVmZwczd3cmJCWC1kWnc0QnlkT0FveElzQWtEZ2k3bVdtZzJnVjlkeFo5M0dMU05jQnNhTE5oUnlmczNUREZCYTRaVkR3SjVvbEo2MUxTS3FqbFpwX1dVYWltWFprWVhHLWVaYi1vaGh3dWhGNW4zakZJd292TWpFYkZ2bmNJcl95Qmw0XzdWc2xN?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/c2f92eaf-71dc-3dc2-8809-0b0e681778f8/exagen-%28xgn%29-q1-2026-earnings.html", "source_name": "Motley Fool", "published_at": "2026-05-12T18:16:06+00:00", "published_display": "12 May 2026 18:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/a653b32d-e201-3b57-9953-a3391b2ceb3b/exagen-inc.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-12T12:30:00+00:00", "published_display": "12 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exagen-inc-xgn-q1-2026-070252248.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T07:02:52+00:00", "published_display": "12 May 2026 07:02", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/b2c43a6c-1b1c-3bbe-86a5-8e1a5b5d2a86/exagen-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-11T17:09:50+00:00", "published_display": "11 May 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses", "summary": "", "url": "https://finance.yahoo.com/m/6c904a18-c9f6-3512-878e-2c441f6ceb3e/record-revenue-growth-and.html", "source_name": "InvestorsHub", "published_at": "2026-05-11T14:59:14+00:00", "published_display": "11 May 2026 14:59", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Hits Record Q1 Revenue, Signals Path to Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNMDRla3NrYTlOcXczSHZsa0RhN1Ztd25SRGNLTFkxZnBLVC1wQXRkTmprYVV0MFlKYW9aLTlzbXcxOTF1bEtmeXNva1Vjc2R5TUh0R1ZmNWpWaGxYcUVwS1E1ZmdrUExFbThTWGhJV3JYZHJ5QUJWNGxaelNOZEpSUTcxNUpEOGNvZVFsa3ZVR2J5cDhoc3pj?oc=5", "source_name": "BriefGlance", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autoimmune test maker Exagen lifts prices, posts record $17.3M quarter", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOTEVDdFhHOWx2ME9fMThOV2pWZUJOQzIxYWJmYktJMERSaWF6ZlJiMzZCX0VWWENxRVEyZzhkOGpMSHpsQWN3YVdpMlVxU3BWOGlIWEdGOGhXc09vLWR4NkhCWHY5djN0TmY5RjRBUXI2T1VMd2lJZmQyQTVNZTgtQzQxSEp3ZVZRWENSdlV0N1FBalFmQWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPZzVRZlk5LUZrQ1JNVk1hNVNGSU5Sa0M1S2hYaGJQcWh6bTJIVFVhbVJwREVYaFMwRmZGMjNBUDZaNEJzM1pHN1R2Y2ZWMkM2RE90d1JvYkZmR3ZWTlBKUjlreUt2Y3F0dmRWRWhXMWNBZGtNeDdhdzZncDZObzFtWEI0WjlHWWpEODVMZ3piall6bjNK?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Exagen (XGN)\u2019s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNcTJ6aXJUdGlSV2VraDF2RkEzWTN6TWRabWlUaUcweWcyWFFZOWJNUm1XbFA0SDBWYVhYNjAtc0R2MGNUVnl3ZU90MHNVS1N4MGhia21ZNzZWOFk3Y1ZTTFVzUXJrN1d2LVhJZGtoX2dlTk9RSDZYZkhXYW5ySHBFYWEybVhMR2V4NW5TUXFzeG1Hb0xJS1E?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Exagen (XGN) Story Is Shifting With A New Analyst Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPaFNYUzlXVHZvcmh0SjNwSWRiREs0SlVOOXd0LU5tYjBUbkJmalcxR0NxTHhKZlJWY0FuanFLZzBVT3FZc2pqZlBNM1RET1RmTlJROWNSMFdseEdidUxxa3FRbDlnVWNBamVJZUlTXzh4Yy1rSTZXeFBydVlxeU95ZnNtWFpJZw?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Selling Exagen Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. Reports Preliminary Financial Results for Q4 and Full Year 2025, Highlighting Record Revenue Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOZkY0aGUwUGZGOVN4c0ktV0k2VGEzYnFnSVlfcjZ2NExiWUtCUUJmekpzblNjaXRmd1VGdUQ3dGY5ZzRXRUJvZ3NIc2VMcTFYaFVKNlVKNGtKcFpKbVJKd08waFRkRjdhTHJWdkFrY284emE1aDlGdHJCSFEyY0VDQjZjZ3l0Wk1rckh2alFCSDNqeXlzMUl5OUNrM1VHa2ZlS1JLdkh0QTIzRGp2ZFlIM3NxTS05bUhPTnJUZllSNWRzWHYtTER0RVBQby1ncXhLcVMwUHlfNHY3Y2U4TDNB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) Stock Price, News & Analysis $XGN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1XU3dmam9QT1lDcFUxanRTckk5ZHBiWXZXRHJlYkhsSHM1aDU2Z1pYVnl3UG1TUUMwNDlLcUo0NDFFUzBVNzR5SENiR2FvUEh4OUtXaW1Dczc?oc=5", "source_name": "MarketBeat", "published_at": "2020-10-22T00:16:44+00:00", "published_display": "22 Oct 2020 00:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ETFs Investing in Exagen, Inc. Stocks", "summary": "This article identifies ETFs that hold stocks of Exagen, Inc. (E08A), a medical/nursing services company. It lists two specific ETFs, iShares Microcap ETF (IWC) and Invesco NASDAQ Future Gen 200 ETF (QQQS), detailing their market value, weight of Exagen stock, issuer, management ", "url": "https://www.tradingview.com/symbols/TRADEGATE-E08A/etfs/", "source_name": "TradingView", "published_at": "2026-07-13T00:12:33", "published_display": "13 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc focuses on autoimmune diagnostics as investors watch strategy", "summary": "Exagen Inc, a specialized diagnostics company, is capturing investor attention with its focus on autoimmune disease diagnostics, particularly systemic lupus erythematosus and rheumatoid arthritis. The company's strategy involves building a strong testing portfolio, securing comme", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exagen-inc-focuses-on-autoimmune-diagnostics-as-investors-watch-strategy/69716857", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T18:41:56", "published_display": "07 Jul 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen(XGN) Stock Options Chain | Quotes & News", "summary": "This document appears to be a placeholder or an incomplete article about Exagen (XGN) stock options, quotes, and news. No actual content beyond the title is provided, making it impossible to extract further details.", "url": "https://www.moomoo.com/stock/XGN-US/options-chain?chain_id=Name1K9-3FXPhg.1l04rc0&global_content=%7B%22promote_id%22%3A13643,%22sub_promote_id%22%3A47,%22f%22%3A%22www.moomoo.com%2Fsg%2Flearn%2Fdetail-what-is-an-investment-portfolio-38083-2110200026%22%7D", "source_name": "Moomoo", "published_at": "2026-07-06T11:11:19", "published_display": "06 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XGN - Exagen Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Exagen Inc. (XGN), covering its recent stock performance, key financial metrics like market capitalization, income, sales, and various ratios. It also includes information on insider and institutional ownership, analyst recom", "url": "https://finviz.com/stock?t=XGN&ty=ocv&ta=1&p=d&ov=list_strike&s=10", "source_name": "Finviz", "published_at": "2026-07-02T21:09:33", "published_display": "02 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 41, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "This page provides financial information for Exagen Inc. (NASDAQ: XGN) on TradingView, specifically focusing on its Price to Sales (forward) metric. The content confirms that the market was closed at the time of viewing, with no trades occurring.", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T22:41:56", "published_display": "30 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for Exagen Inc. (NASDAQ: XGN). It is presented within the context of TradingView's financial analysis tools, indicating that the data is provided by ICE Data Services and FactSet. The content is primarily a d", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T08:41:21", "published_display": "30 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support Level - Momentum Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPc1F4VTdabnVNeVdaS190SnBtTzJ5dm94RG9qVXc2TEFmVlE1R3d3YjdreXZ0dVlBamlnYTh2bDU2TnlUTl9INkZKOWJlTFFXLWh4dVBNaWNka00yRExieVdnYV85VjdoVl9BcmlhanNHaW05d0QxNEI4dE1FVFJ5WVBsYlZkRW0zQWtsUHkyakNXOHhLeUtDUWtEbHVJcFJYRlVNMUpNbVl4S28teWNjNTVoZ0JmTUVPMkM4?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support Level - NAAIM Leverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNdEo0NlRfQTlfUTlSVnVoM000VEFnd292akRmZm0xdXJhYm92Q255MlhYZklVRE9xbFdUQlBmT0g1MGx5WXhCcEY3RnJ6TkVHZGpOMm9wSWVZWkFLTkpJckFnazNLc3ItTzEtZDZOa2hHRjk4UVpsWlo2empWQjRvVHBWTmJUWjdGbTYwclBQZ0U0Wmo5MUk3TFJoVjNYdkgxRy05b3ZMd19XZVRLWTNqa0NlbVg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Exagen, Inc. \u2013 LS:A2PRXT", "summary": "This article provides financial information for Exagen, Inc. (A2PRXT) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of viewing. The content appears to be a stub or an incomplete dat", "url": "https://www.tradingview.com/symbols/LS-A2PRXT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:40:25", "published_display": "30 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "This article provides financial context for Exagen Inc. (NASDAQ: XGN), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial snapshot or data point from TradingView, without additional analysis or narrative.", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T17:39:14", "published_display": "29 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2PRXT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Exagen, Inc. (A2PRXT) stock, including analyst price targets, past performance, and key financial data. According to analysts, the stock has a max estimate of 8.79 EUR and a min estimate of 7.03 EUR. The article also covers reported earnings, ", "url": "https://www.tradingview.com/symbols/LS-A2PRXT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T16:39:15", "published_display": "29 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "The article focuses on the \"Price to book forward\" metric for Exagen Inc. (NASDAQ: XGN). It provides general financial and market information related to the company within the TradingView platform, without specific financial figures or detailed analysis. The content appears to be", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:10:52", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Exagen, Inc. \u2013 GETTEX:E08A", "summary": "This article provides financial information for Exagen, Inc. (GETTEX:E08A), specifically focusing on its Enterprise Value to EBIT forward metric. The content highlights the company's financial data as part of its stock market listing on Gettex, indicating a focus on investor-rela", "url": "https://www.tradingview.com/symbols/GETTEX-E08A/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:09:22", "published_display": "28 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "This article displays the forward Enterprise Value to EBITDA for Exagen Inc. (NASDAQ: XGN) on TradingView. It provides financial data related to the company, indicating the market is currently closed with no trades. The information is presented on the TradingView platform, which ", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:41:10", "published_display": "28 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Exagen Inc. \u2013 NASDAQ:XGN", "summary": "The article provides financial information for Exagen Inc. (NASDAQ:XGN), specifically highlighting its enterprise value to revenue forward metric. This data is presented within the context of TradingView's platform, offering an overview of the company's financials for market anal", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:35", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen, Inc. Actuals & Estimates (NASDAQ:XGN)", "summary": "This article provides key financial actuals, estimates, and analyst forecasts for Exagen Inc. (NASDAQ: XGN). It details recent stock performance, future price predictions, upcoming earnings dates, and current financial metrics like market capitalization, revenue, and EBITDA. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:40:48", "published_display": "25 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XGN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Exagen Inc. (XGN) stock, including its current price, analyst forecasts, and various financial metrics. It highlights the company's price target of $8.57, with analysts predicting a maximum of $10.00 and a minimum of $8.00. The article also co", "url": "https://www.tradingview.com/symbols/NASDAQ-XGN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:48", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Initiates Exagen at Buy With $8 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/roth-capital-initiates-exagen-buy-112451913.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:24:51+00:00", "published_display": "25 Jun 2026 11:24", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat", "summary": "Roth Capital has initiated coverage on Exagen (XGN) with a Buy rating and a price target of $8.00. While analysts see potential upside, GuruFocus indicates the stock is currently 51.0% overvalued with a GF Value\u2122 of $3.00, suggesting caution due to mixed financial metrics and mod", "url": "https://www.gurufocus.com/news/8931447/xgn-initiates-coverage-on-exagen-roth-capital-assigns-buy-rating", "source_name": "GuruFocus", "published_at": "2026-06-25T12:11:42", "published_display": "25 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Exagen Inc For: 24 June By Investing.com", "summary": "This article reports on the filing of Form 4 for Exagen Inc. (XGN) on June 24th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article also provides curre", "url": "https://za.investing.com/news/stock-market-news/form-4-exagen-inc-for-24-june-93CH-4342387", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T05:40:48", "published_display": "25 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst", "summary": "Roth Capital has initiated coverage of Exagen (XGN) with a Buy rating and an $8 price target, driven by the strength of its autoimmune testing range, particularly the AVISE CTD test. Despite a moderate GF Score\u2122 of 58 and concerns about financial strength and profitability, the c", "url": "https://www.gurufocus.com/news/8930745/exagen-xgn-gains-buy-rating-with-8-price-target-from-analyst", "source_name": "GuruFocus", "published_at": "2026-06-25T04:10:57", "published_display": "25 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Exagen Inc For: 22 June By Investing.com", "summary": "This article announces the filing of Form 4 for Exagen Inc. on June 22. It is a brief financial news update from Investing.com reporting the regulatory filing related to insider transactions for the company.", "url": "https://au.investing.com/news/stock-market-news/form-4-exagen-inc-for-22-june-93CH-4498466", "source_name": "Investing.com Australia", "published_at": "2026-06-23T03:11:37", "published_display": "23 Jun 2026 03:11", "sentiment": "negative", "sentiment_pct": 42, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) director granted 37,500 stock options at $4.31 strike", "summary": "Exagen Inc. director Chas McKhann was granted 37,500 stock options at an exercise price of $4.31 per share. These options will vest fully on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues his board service. Fol", "url": "https://www.stocktitan.net/sec-filings/XGN/form-4-exagen-inc-insider-trading-activity-a829ca61bb89.html", "source_name": "Stock Titan", "published_at": "2026-06-22T17:11:38", "published_display": "22 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31", "summary": "Exagen Inc. director Frank Stokes was granted 37,500 stock options at an exercise price of $4.31 per share. These options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues his board service. Following", "url": "https://www.stocktitan.net/sec-filings/XGN/form-4-exagen-inc-insider-trading-activity-75ddec22e69b.html", "source_name": "Stock Titan", "published_at": "2026-06-22T17:11:37", "published_display": "22 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) director Scott Kahn receives 37,500 stock options grant", "summary": "Exagen (XGN) director Scott D. Kahn was granted 37,500 stock options with an exercise price of $4.31 per share, expiring on June 8, 2036. These options will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, provided Kahn re", "url": "https://www.stocktitan.net/sec-filings/XGN/form-4-exagen-inc-insider-trading-activity-d0ddb7fa69bb.html", "source_name": "Stock Titan", "published_at": "2026-06-22T17:11:37", "published_display": "22 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOM1dyWkVoVWkxT0x0bXpOa21GQjBCMlozcmE2Z0gwRU9LcVlwUGtYRTJMZVY2NTQtZE5RUklja2JIYzVGLVZzNTdLOFQ4TVJlRE1zajZ6alM4MGNJRElzMnctYzFGMUJwblJOZ28wMkF0dElCUXRkVG15blZXbEFlQjFTLXB4Y3FaVHJJdWI5UTdjX0Y1WThNdA?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Exagen Inc (XGN), noting its current valuation score of 7.76, placing it 56th out of 76 in the Healthcare Providers & Services industry. The P/E ratio is reported as -5.10, with other key metrics like P/B, P/S, and P/CF not yet discl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:54", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Exagen Inc (XGN)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock performance data for XG", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:15", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Exagen Inc (XGN), detailing its performance across various business segments. It shows that Commercial, Government, and Client segments are the primary contributors to the company's revenue, with specific proportions for each. The dat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:15", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Exagen Inc (XGN) currently holds a financial score of 6.90, ranking 59 out of 76 in the Healthcare Providers & Services industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue saw an 11.67% year-over-year increase, with ne", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T14:40:41", "published_display": "17 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Exagen Inc (XGN), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. The stock currently has a price momentum score of 8.90, trading between resistance at", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/technical", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:34", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Institutional Confidence", "summary": "Exagen Inc (XGN) has an institutional shareholding score of 5.00, placing it 49th out of 76 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 58.04%, marking a 7.71% quarter-over-quarter decrease. James Simons is the largest inst", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:34", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Exagen Inc (XGN) has an earnings forecast score of 8.57, ranking 10th in the Healthcare Providers & Services industry, with an average analyst price target of $15.00. Based on 7 analysts, the stock currently holds a \"Buy\" rating. The company's expected revenue for the next quarte", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:34", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Shareholders Approve Directors, Auditor and Pay Package", "summary": "Exagen Inc. held its 2026 annual meeting where shareholders re-elected two Class I directors, Tina S. Nova and Scott Kahn, to three-year terms. They also ratified BDO USA, P.C. as the independent auditor and approved the compensation for named executive officers, indicating stron", "url": "https://www.theglobeandmail.com/investing/markets/stocks/XGN-Q/pressreleases/2408837/exagen-shareholders-approve-directors-auditor-and-pay-package/", "source_name": "The Globe and Mail", "published_at": "2026-06-11T12:08:55", "published_display": "11 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exagen-announces-publication-systematic-review-130000586.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T13:00:00+00:00", "published_display": "01 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/much-upside-left-exagen-xgn-135501041.html", "source_name": "Zacks", "published_at": "2026-05-28T13:55:01+00:00", "published_display": "28 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOM3RoR2stVmZwczd3cmJCWC1kWnc0QnlkT0FveElzQWtEZ2k3bVdtZzJnVjlkeFo5M0dMU05jQnNhTE5oUnlmczNUREZCYTRaVkR3SjVvbEo2MUxTS3FqbFpwX1dVYWltWFprWVhHLWVaYi1vaGh3dWhGNW4zakZJd292TWpFYkZ2bmNJcl95Qmw0XzdWc2xN?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/c2f92eaf-71dc-3dc2-8809-0b0e681778f8/exagen-%28xgn%29-q1-2026-earnings.html", "source_name": "Motley Fool", "published_at": "2026-05-12T18:16:06+00:00", "published_display": "12 May 2026 18:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/a653b32d-e201-3b57-9953-a3391b2ceb3b/exagen-inc.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-12T12:30:00+00:00", "published_display": "12 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exagen-inc-xgn-q1-2026-070252248.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T07:02:52+00:00", "published_display": "12 May 2026 07:02", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/b2c43a6c-1b1c-3bbe-86a5-8e1a5b5d2a86/exagen-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-11T17:09:50+00:00", "published_display": "11 May 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses", "summary": "", "url": "https://finance.yahoo.com/m/6c904a18-c9f6-3512-878e-2c441f6ceb3e/record-revenue-growth-and.html", "source_name": "InvestorsHub", "published_at": "2026-05-11T14:59:14+00:00", "published_display": "11 May 2026 14:59", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Hits Record Q1 Revenue, Signals Path to Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNMDRla3NrYTlOcXczSHZsa0RhN1Ztd25SRGNLTFkxZnBLVC1wQXRkTmprYVV0MFlKYW9aLTlzbXcxOTF1bEtmeXNva1Vjc2R5TUh0R1ZmNWpWaGxYcUVwS1E1ZmdrUExFbThTWGhJV3JYZHJ5QUJWNGxaelNOZEpSUTcxNUpEOGNvZVFsa3ZVR2J5cDhoc3pj?oc=5", "source_name": "BriefGlance", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Autoimmune test maker Exagen lifts prices, posts record $17.3M quarter", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOTEVDdFhHOWx2ME9fMThOV2pWZUJOQzIxYWJmYktJMERSaWF6ZlJiMzZCX0VWWENxRVEyZzhkOGpMSHpsQWN3YVdpMlVxU3BWOGlIWEdGOGhXc09vLWR4NkhCWHY5djN0TmY5RjRBUXI2T1VMd2lJZmQyQTVNZTgtQzQxSEp3ZVZRWENSdlV0N1FBalFmQWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPZzVRZlk5LUZrQ1JNVk1hNVNGSU5Sa0M1S2hYaGJQcWh6bTJIVFVhbVJwREVYaFMwRmZGMjNBUDZaNEJzM1pHN1R2Y2ZWMkM2RE90d1JvYkZmR3ZWTlBKUjlreUt2Y3F0dmRWRWhXMWNBZGtNeDdhdzZncDZObzFtWEI0WjlHWWpEODVMZ3piall6bjNK?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Exagen (XGN)\u2019s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNcTJ6aXJUdGlSV2VraDF2RkEzWTN6TWRabWlUaUcweWcyWFFZOWJNUm1XbFA0SDBWYVhYNjAtc0R2MGNUVnl3ZU90MHNVS1N4MGhia21ZNzZWOFk3Y1ZTTFVzUXJrN1d2LVhJZGtoX2dlTk9RSDZYZkhXYW5ySHBFYWEybVhMR2V4NW5TUXFzeG1Hb0xJS1E?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Exagen (XGN) Story Is Shifting With A New Analyst Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPaFNYUzlXVHZvcmh0SjNwSWRiREs0SlVOOXd0LU5tYjBUbkJmalcxR0NxTHhKZlJWY0FuanFLZzBVT3FZc2pqZlBNM1RET1RmTlJROWNSMFdseEdidUxxa3FRbDlnVWNBamVJZUlTXzh4Yy1rSTZXeFBydVlxeU95ZnNtWFpJZw?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Selling Exagen Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen Inc. Reports Preliminary Financial Results for Q4 and Full Year 2025, Highlighting Record Revenue Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOZkY0aGUwUGZGOVN4c0ktV0k2VGEzYnFnSVlfcjZ2NExiWUtCUUJmekpzblNjaXRmd1VGdUQ3dGY5ZzRXRUJvZ3NIc2VMcTFYaFVKNlVKNGtKcFpKbVJKd08waFRkRjdhTHJWdkFrY284emE1aDlGdHJCSFEyY0VDQjZjZ3l0Wk1rckh2alFCSDNqeXlzMUl5OUNrM1VHa2ZlS1JLdkh0QTIzRGp2ZFlIM3NxTS05bUhPTnJUZllSNWRzWHYtTER0RVBQby1ncXhLcVMwUHlfNHY3Y2U4TDNB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exagen (XGN) Stock Price, News & Analysis $XGN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1XU3dmam9QT1lDcFUxanRTckk5ZHBiWXZXRHJlYkhsSHM1aDU2Z1pYVnl3UG1TUUMwNDlLcUo0NDFFUzBVNzR5SENiR2FvUEh4OUtXaW1Dczc?oc=5", "source_name": "MarketBeat", "published_at": "2020-10-22T00:16:44+00:00", "published_display": "22 Oct 2020 00:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 94, "total_relevant": 51, "sentiment_summary": {"positive": 16, "negative": 3, "neutral": 32, "score": 54, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.0, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 9.35, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.45, "latest_week": "2026-07-10", "one_week_move": -2.0, "four_week_move": -4.7, "twelve_week_move": 44.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.979924, "market_dynamics_buy_signal": false, "relative_strength": -40.647882, "fair_value_gap": 6.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 43.3289, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.0% over one week, -4.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "TradingKey", "count": 7}, {"label": "Market source", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "GuruFocus", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "AD HOC NEWS", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 8}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.0% over one week, -4.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ETFs Investing in Exagen, Inc. Stocks"}], "updated_at": "2026-07-16T11:44:53.028004+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}